Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

NEUROCR Form 4 June 01, 200	INE BIOSCIENC	CES INC								
FORM	ЛД								PPROVAL	
	STATES S		RITIES A shington	N OMB Number:	3235-0287					
Check the if no lon subject the Section Form 4 de	MENT OF	CHAN	IGES IN SECUF	Expires: Estimated burden hou response	urs per					
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940										
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> MITCHELL W THOMAS			2. Issuer Name and Ticker or Trading Symbol NEUROCRINE BIOSCIENCES			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
			INC [N	-						
(Month/			Month/I	Date of Earliest Transaction Ionth/Day/Year) 5/29/2009			Officer (give titleOther (specify below) below)			
			endment, Dannent, Dannen, Danne	-	al	6. Individual or Joint/Group Filing(CheckApplicable Line)_X_ Form filed by One Reporting Person				
LA QUINT	[°] A, CA 92253						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-I	Derivativ	e Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		Date, if		Disposed (Instr. 3,	l (A) or l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each clas	ss of secu	urities bene	Pers infor requ	ons who res mation cont red to resp	or indirectly. spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

(Instr. 3)	Price of Derivative Security	(Month/I	Day/Year) (Instr	. 8)	Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)					
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (1)	\$ 3.07	05/29/2009	А		15,000		06/29/2009	05/29/2016	Common Stock	15,000

Reporting Owners

Reporting Owner Name / Address	Relationships							
I O	Director	10% Owner	Officer	Other				
MITCHELL W THOMAS 48030 PASO TIEMPO LA. LA QUINTA, CA 92253	Х							
Signatures								
Margaret E. Valeur-Jensen, By Attorney		06/01/2009						
<u>**</u> Signature of Reporting Per		Date						

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents option of which 1/12th of the shares underlying the option becomes vested and exercisable on June 29, 2009, an additional 1/12th of the shares underlying the option becomes vested and exercisable each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.